Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lundbeck Acquires Prexton Therapeutics | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Lundbeck Acquires Prexton Therapeutics

Lundbeck will pay €100 million upfront plus €805 million in development and sales milestones

By: Betsy Louda

, Contract Pharma

Lundbeck and Prexton Therapeutics BV (Prexton) have signed an agreement in which Lundbeck will acquire Prexton. Under terms of the agreement, Lundbeck will pay €100 million upfront plus €805 million in development and sales milestones.

 

Because of the acquisition, Lundbeck will obtain global rights for Prexton’s foliglurax, which is currently in clinical phase II testing for the symptomatic treatment of OFF-time reduction in Parkinson’s disease and dyskinesia (uncontrolled movements) including Levodopa Induced Dyskinesia (LID). 

 

“We are very excited to be working with Lundbeck, a company with a strong history and focus on diseases of the central nervous system,” said François Conquet, Ph.D., founder and chief executive officer, Prexton. “Lundbeck shares our vision for the development of foliglurax to help patients living with Parkinson’s disease.”

 

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters